Copyright
©The Author(s) 2017.
World J Gastroenterol. Feb 21, 2017; 23(7): 1171-1179
Published online Feb 21, 2017. doi: 10.3748/wjg.v23.i7.1171
Published online Feb 21, 2017. doi: 10.3748/wjg.v23.i7.1171
Figure 4 Thymoquinone treatment inhibits β-catenin translocation into LoVo cell nuclei.
An immunofluorescence assay was performed on LoVo cells using a β-catenin primary antibody and a secondary antibody (1:250) producing green fluorescence; DAPI (blue fluorescence) was included to stain cell nuclei. Merged β-catenin and DAPI (green and blue, respectively) signals are shown. The indicated treatments were assessed. PGE2: Prostaglandin E2; TQ: Thymoquinone.
- Citation: Hsu HH, Chen MC, Day CH, Lin YM, Li SY, Tu CC, Padma VV, Shih HN, Kuo WW, Huang CY. Thymoquinone suppresses migration of LoVo human colon cancer cells by reducing prostaglandin E2 induced COX-2 activation. World J Gastroenterol 2017; 23(7): 1171-1179
- URL: https://www.wjgnet.com/1007-9327/full/v23/i7/1171.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i7.1171